Authors: Zdravkovic, M Christiansen, T Eliot, L Agersoe, H Thomsen, MS Falch, JF Sogaard, B Ynddal, L Ilondo, MM

Citation: M. Zdravkovic et al., The pharmacokinetics, pharmacodynamics, safety and tolerability following 7 days daily oral treatment with NN703 in healthy male subjects, GROWTH H I, 11(1), 2001, pp. 41-48

Authors: Gorodkin, J Sogaard, B Bay, H Doll, H Kolster, P Brunak, S

Citation: J. Gorodkin et al., Recognition of environmental and genetic effects on barley phenolic fingerprints by neural networks, COMPUT CHEM, 25(3), 2001, pp. 301-307

Authors: Agerso, H Ynddal, L Sogaard, B Zdravkovic, M

Citation: H. Agerso et al., Pharmacokinetic and pharmacodynamic modeling of NN703, a growth hormone secretagogue, after a single po dose to human volunteers, J CLIN PHAR, 41(2), 2001, pp. 163-169

Authors: Zdravkovic, M Sogaard, B Ynddal, L Christiansen, T Agerso, H Thomsen, MS Falch, JE Ilondo, MM

Citation: M. Zdravkovic et al., The pharmacokinetics, pharmacodynamics, safety and tolerability of a single dose of NN703, a novel orally active growth hormone secretagogue in healthy male volunteers, GROWTH H I, 10(4), 2000, pp. 193-198

Authors: Brunner, GA Sendlhofer, G Wutte, A Ellmerer, M Sogaard, B Siebenhofer, A Hirschberger, S Krejs, GJ Pieber, TR

Citation: Ga. Brunner et al., Pharmacokinetic and pharmacodynamic properties of long-acting insulin analogue NN304 in comparison to NPH insulin in humans, EXP CL E D, 108(2), 2000, pp. 100-105

Authors: Jacobsen, LV Sogaard, B Riis, A

Citation: Lv. Jacobsen et al., Pharmacokinetics and pharmacodynamics of a premixed formulation of solubleand protamine-retarded insulin aspart, EUR J CL PH, 56(5), 2000, pp. 399-403